Company news

JCR Pharmaceuticals Co., Ltd. news in 2025

JCR Pharmaceuticals Co., Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Italfarmaco and JCR Pharmaceuticals Announce Commercialisation Agreement for Givinostat in Japan and Strategic Collaboration in Rare Disease

December 24, 2025

FY2025 Second Quarter Results Briefing Session - Script（1,455KB）

November 4, 2025

FY2025-Q2 Financial Report (Jul. 1-Sep. 30, 2025)（536KB）

October 30, 2025

JCR Pharmaceuticals Enhances Delivery of AAV Gene Therapy to Central Nervous System and Muscle with Novel Capsid Engineering Platform Technology

October 7, 2025

JCR Pharmaceuticals Announces Licensing Agreement with Menagen to Commercialize Agalsidase Beta BS I.V. Infusion [JCR] Across Nine MENAT Markets

October 1, 2025

JCR Pharmaceuticals to Present at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

September 30, 2025

Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by Ministry of Health, Labour and Welfare of Japan

September 29, 2025

JCR Pharmaceuticals and Alexion Achieve Milestone in Collaborative Neurodegenerative Disease Program

September 19, 2025

JCR Pharmaceuticals Celebrates its 50th Anniversary of Advancing Science and Changing Lives

September 12, 2025

JCR Pharmaceuticals Presents Long-Term Clinical Data on Pabinafusp Alfa for the Treatment of Mucopolysaccharidosis Type II (MPS II) at ICIEM 2025

September 8, 2025

MEDIPAL HOLDINGS and JCR Pharmaceuticals Sign Global Licensing and Japan Co-Development Agreement for JR-479, a Novel Therapy for GM2 Gangliosidosis

September 2, 2025

JCR Pharmaceuticals to Present at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) 2025

August 28, 2025

FY2025-Q1 Financial Report (Apr. 1-Jun. 30, 2025)（340KB）

July 30, 2025

JCR Pharmaceuticals Selected for Japan’s Regenerative Medicine CDMO Subsidy Program

July 16, 2025

JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform

July 15, 2025

JCR Pharmaceuticals Enters License Agreement with Alexion for Proprietary JUST-AAV Capsids to be Used in the Development of Genomic Medicines

July 8, 2025

JCR Pharmaceuticals Announces the Achievement of Enrollment in the JR-141 Global Phase III Clinical Trial

July 2, 2025

Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by European Commission (EC)

June 24, 2025

JCR Pharmaceuticals Announces Launch of Mucopolysaccharidosis (MPS) Type II Disease Awareness Film Featured in The Next Frontier Series

June 18, 2025

JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website

June 6, 2025

JCR Pharmaceuticals Presents Preclinical Gene Therapy Data that Demonstrate Promising CNS Uptake at American Society of Gene and Cell Therapy 28th Annual Meeting

May 16, 2025

Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by the U.S. FDA

May 7, 2025

Decks in 2025